Previous studies on patient‐reported outcomes in psoriasis often included topical therapies, conventional systemic therapies, or TNF‐α inhibitors, whereas our study exclusively focused on patients undergoing treatment with IL‐17/IL‐23 inhibitors, one of the most widely prescribed classes of biologics in current practice. Here, TNF is linked to psoriasis.